Everolimus
Advanced progressive NET (RADIANT-3, RADIANT-4); RCC and HR-positive breast cancer after prior therapy
every 28 days
Dose-dense AC → T
Node-positive or high-risk early breast cancer, adjuvant or neoadjuvant
every 14 days × 4
KEYNOTE-522 (pembrolizumab + chemotherapy, then adjuvant pembrolizumab)
Stage II-III triple-negative breast cancer
every 21 days × 4
Trastuzumab deruxtecan 5.4 mg/kg
HER2-positive metastatic breast cancer second line; HER2-low or ultralow after chemotherapy or endocrine therapy; HER2-mutant NSCLC
every 21 days
Sacituzumab govitecan
Metastatic TNBC after two lines (one for metastatic disease); HR-positive after endocrine therapy and two chemotherapies
every 21 days
Capecitabine (post-neoadjuvant)
Residual invasive disease after neoadjuvant chemotherapy, HER2-negative
every 21 days × 6-8
Olaparib (adjuvant, OlympiA)
Germline BRCA1/2, HER2-negative, high-risk early breast cancer after chemotherapy
every 28 days × 13
CDK4/6 inhibitor + aromatase inhibitor
HR-positive, HER2-negative advanced breast cancer, first line (and adjuvant abemaciclib or ribociclib for high-risk early disease)
every 28 days